Saturday 17 October 2026
Export PRFX’s income statement to Excel — free account
PainReform Ltd.
PRFX Healthcare Drug Manufacturers Specialty & Generic
PainReform Ltd.’s revenue for fiscal 2025 (year ended December 2025) was $17,000.00.
0.81
0.04
−4.71%
Follow PRFX
| Jun '26 | Jun '25 | Jun '24 | Mar '24 | Older periods | |
|---|---|---|---|---|---|
| 0.00% | 0.00% | 0.00% | (185.44%) |
+8 more TTM periods Free account |
|
| 0.00% | 0.00% | 0.00% | (126.16%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
0.00% | 0.00% | 0.00% | (489.87%) | |
Average Days of Receivables |
— | — | — | — | |
Free Cash Flow per Share |
0.00 | 0.00 | 0.00 | (754.64) | |
Free Cash Flow |
(13.08) | (15.75) | (15.73) | (12.75) | |
Capital Expenditures |
(0.02) | — | (0.02) | (0.04) | |
| Other line items | |||||
Cash ROIC |
(46.66%) | (131.97%) | (2,092.21%) | (206.30%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
— | — | — | 0.00 | |
Research and Development Expense of Revenue |
— | — | — | 0.00% | |
Selling, General and Administrative Expense of Revenue |
— | — | — | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
0.00 | 0.00 | 0.00 | 1.28 | |
Depreciation/Fixed assets |
28.48 | 7.65 | 0.50 | 0.46 | |
Capex/Depreciation |
(0.03) | 0.00 | (1.10) | (2.12) | |
Revenue per Share |
— | — | — | 0.00 | |
Operating CF per Share |
0.00 | 0.00 | 0.00 | (752.27) | |
Capex per Share |
0.00 | — | 0.00 | (2.37) | |
Capex to Sales |
0.00 | — | 0.00 | 0.00 |
Columns are period end dates